Study to Evaluate the Safety and Efficacy of PEER Interactive Versus Treatment as Usual in Subjects With a Primary Diagnosis of Depression
Study Details
Study Description
Brief Summary
This is a prospective, multicenter, randomized, double-blind, controlled study to evaluate the effectiveness of PEER Interactive to inform treatment in subjects with a primary diagnosis of depression with comorbidity of non-psychotic behavioral disorders versus treatment as usual, as determined by the investigator. The primary measurement for improvement of the subjects depression will be a self-evaluation questionnaire, Quick Inventory of Depressive Symptomatology-Self Report 16, but the investigators will also collect information on their clinical global improvement and any reduction in adverse events.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This study is prospective in nature. Subjects in the control group will be treated according to treatment as usual and best judgment of the treating physician. For the experimental group the treating physician will follow the guidance of the subject's PEER Interactive Report as regards sensitivity to on-label medications and classes of medication.
The subjects will be washed out of all current medications prior to having an EEG, which is necessary to generate the PEER Interactive Report. The wash out period for outpatients is no longer than 14 days.
The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health. The subjects will also be closely evaluated to determine if they are experiencing any psychiatric specific adverse events. The investigator is allowed to treat the patient according to their best medical judgment, which may include adding or changing medications, seeing the patient more frequently, or other interventions such as the use of sleep aids.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Informed by PEER Interactive Report The PEER Interactive Report -This study is prospective in nature. For subjects in the experimental group, the treating physician will follow the guidance of the subject's PEER Interactive Report as regards sensitivity to on-label medications and classes of medication. The subjects will be washed out of all current medications prior to having an EEG, which is necessary to generate the PEER Interactive Report. The wash out period for outpatients is no longer than 14 days. The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health. |
Device: PEER Interactive Report
The PEER Interactive Report provides information comparing the subject's Quantitative Electroencephalography (QEEG) to a database of outcomes from patients with similar QEEG results, and how they responded to on-label treatments. This report provides a probability of how this subject will respond to treatment based upon a comparison of similar subjects in the database.
|
| No Intervention: No Report This study is prospective in nature. Subjects in the control group will be treated according to treatment as usual and best judgment of the treating physician. PEER Interactive Report is not provided to the investigator. The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health. |
Outcome Measures
Primary Outcome Measures
- Quick Inventory of Depressive Symptomatology - Self Reported 16 (QIDS-SR16) [6 months]
A 16 question self administer survey on the status of the subject's depression. The measurement will be taken until the completion of the study (6 months)or until the subject achieves maximum medical improvement.
Secondary Outcome Measures
- Clinical Global Impression (CGI) [6 months]
A CGI for Improvement (CGI-I) and a CGI of Severity (CGI-S) will be measured at each visit during the study or until the subject reaches maximum medical improvement
- Concise Health Risk Tracking (CHRT-7SR) [6 months]
Self reported survey on suicidality will be conducted at each visit until the completion of the study or until the subject reaches maximum medical improvement.
- Post traumatic stress disorder checklist - civilian [6 months]
A 17 question self-reported measure of the Diagnostic and Statistical Manual (DSM)-IV symptoms of PTSD.
- Maximum Medical Improvement (MMI) [6 months]
At what point in time, if ever, does the subject reach their maximum medical improvement.
Other Outcome Measures
- Number of Subjects with Adverse Events as a Measure of Safety and Tolerability [6 months]
Noting the frequency and severity of psychiatric specific adverse events to determine if the information provided in the PEER Interactive Report results in providing treatment that was better tolerated than treatment as usual.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Must speak and read English
-
Must be able to provide written informed consent
-
A primary diagnosis of a DSM-IV depressive disorder
-
Co-morbidities of non-psychotic behavioral disorders, including PTSD and mild Traumatic Brain Injury (mTBI) are eligible to participate.
-
Able to stop all medications (wash out) for 5 half-lves of all medication(s) which affect the EEG. Outpatient subjects are eligible if they can be washed out of their medications in 14 days or less.
-
Ability to comply with the requirements of the study
Exclusion Criteria:
-
Diagnosis of a psychotic disorder
-
History of, or current, open head trauma
-
Subjects who would not be good candidates to be washed out of their medications, in the opinion of the investigator.
-
History of craniotomy, cerebral metastases, cerebrovascular accident, current diagnosis of seizure disorder, bipolar disorder, schizophrenia, schizo-affective disorder, dementia, mental retardation, or major depression with psychotic features, or use of depot neuroleptics in the last 12 months.
-
Clinically significant medical illness, including thyroid disorders.
-
Participation in any other therapeutic drug study within 60 days preceding inclusion in the study.
-
Know pregnancy and/or lactation, or intent to become pregnant during the study.
-
Chronic or acute pain requiring prescription medication(s).
-
Candidates with any metal, shrapnel or other similar objects in the head that could affect the QEEG
-
Candidates that are currently stable and considered to be at maximum medical improvement on current medications.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Walter Reed National Military Medical Center | Bethesda | Maryland | United States | 20889 |
| 2 | Fort Belvoir Community Hospital | Fort Belvoir | Virginia | United States | 22060 |
Sponsors and Collaborators
- MYnd Analytics
Investigators
- Principal Investigator: Daniel Iosifescu, MD, PhD, Langone Center, NYU
- Study Director: Michael Metzig, BA, MYnd Analytics, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CNSR011